Logo of Pathkey.AI (ASX:PKY)Latest Pathkey.AI (ASX:PKY) News

Page 3
Page 3 of 3

How Pathkey.AI’s New Partnership Could Revolutionise Early-Phase Clinical Trials

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.
Ada Torres
12 Nov 2025

Pathkey.AI Validates AI Platform and Revamps Board Amid Commercial Push

Pathkey.AI reports strong validation of its TrialKey AI platform’s predictive accuracy and announces key leadership changes as it advances toward commercial scale.
Ada Torres
31 Oct 2025

Pathkey.AI’s TrialKey AI Drives 43.6% Average Share Price Jump on Clinical Trial Wins

Pathkey.AI’s TrialKey platform continues to validate its AI-driven clinical trial success predictions, with September 2025 seeing an average 43.6% share price increase across flagged biotech stocks.
Ada Torres
9 Oct 2025

Pathkey.AI Elevates TrialKey with Drug-Level AI, Pioneering Drug Discovery

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.
Ada Torres
18 Sept 2025

Pathkey.AI’s TrialKey AI Predicts Clinical Trial Success with 73% Accuracy

Pathkey.AI’s TrialKey platform has demonstrated a 73% alignment with actual biotech trial outcomes, showing an average hypothetical share price gain of 76%, underscoring AI’s growing role in clinical trial prediction and biotech investing.
Ada Torres
8 Sept 2025

Pathkey.AI Slashes Losses Amid Revenue Collapse in FY2025

Pathkey.AI Ltd reported a substantial reduction in its annual loss to $1.45 million for FY2025, despite a dramatic 93% plunge in revenue to just $27,783. The company’s financials reveal a cautious recovery phase with significant equity injections and a new cryptocurrency investment.
Sophie Babbage
29 Aug 2025